gvtcx

CM/PHR/22/5687 - NHS National Proprietary Low Molecular Weight Heparins

NHS England Published 10 Aug 2023 Contracts Finder

key details

Value£186,609,000
Statuscomplete
Category (CPV) 33600000
Deadline3 May 2023
Contract start1 Sept 2023
Contract end31 Aug 2025
Procedureopen
SME suitableYes
OCIDocds-b5fd17-d50ab890-a60d-4303-954e-23b2becba9c2

Awards (8)

This procurement was awarded to 8 suppliers. Values shown are per-award; the notice total is £186,609,000.

SupplierValueDateStatus
Aventis Pharma ltd t/a Sanofi shared £186,609,000 13 Jul 2023 active
Dr.Reddy's Laboratories (UK) Limited shared £186,609,000 13 Jul 2023 active
LEO Pharma shared £186,609,000 13 Jul 2023 active
Mylan shared £186,609,000 13 Jul 2023 active
Pfizer Ltd shared £186,609,000 13 Jul 2023 active
ROVI Biotech Ltd shared £186,609,000 13 Jul 2023 active
Techdow Pharma England Ltd shared £186,609,000 13 Jul 2023 active
Tetris Pharma Ltd shared £186,609,000 13 Jul 2023 active

description

NHS National Framework for low molecular weight heparin products and fondaparinux

Offer reference number: CM/PHR/22/5687

Period of framework: 1 September 2023 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
10 Aug 2023 Award (award) · 7ce0cbe2-40f9-4221-b47c-9dbc14b90186-671062

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.